Management of severe hyponatremia: Infusion of hypertonic saline and desmopressin or infusion of vasopressin inhibitors?

Antonios H. Tzamaloukas
Joseph I. Shapiro
Dominic S. Raj
George Washington University
Glen H. Murata
Robert H. Glew

See next page for additional authors

Follow this and additional works at: http://hsr.himmelfarb.gwu.edu/smhs_medicine_facpubs

Part of the Medicine and Health Sciences Commons

Recommended Citation
MANAGEMENT OF SEVERE HYponATREMIA: INFUSION OF HYPERTONIC SALINE AND DESMOPRESSIN OR INFUSION OF VASOPRESSIN INHIBITORS?

Antonios H. Tzamaloukas, MD, Joseph I. Shapiro, MD, Dominic S. Raj, MD, Glen H. Murata, MD, Robert H. Glew, PhD and Deepak Malhotra, MD, PhD

Abstract: Rapid correction of severe hyponatremia carries the risk of osmotic demyelination. Two recently introduced methods of correction of hyponatremia have diametrically opposite effects on aquaresis. Inhibitors of vasopressin V2 receptor (vaptans) lead to the production of dilute urine, whereas infusion of desmopressin causes urinary concentration. Identification of the category of hyponatremia that will benefit from one or the other treatment is critical. In general, vaptans are effective in hyponatremias presenting with concentrated urine and, with the exception of hypovolemic hyponatremia, can be used as their primary treatment. Desmopressin is effective in hyponatremias presenting with dilute urine or developing urinary dilution after saline infusion. In this setting, desmopressin infusion helps prevent overcorrection of the hyponatremia. Monitoring of the changes in serum sodium concentration as a guide to treatment changes is imperative regardless of the initial treatment of severe hyponatremia.

Key Indexing Terms: Hyponatremia; Vaptans; Desmopressin.

Hypotonic or isotonic saline is infused to correct severe neurological manifestations or symptomatic hypovolemia. In severe cases of hyponatremia, the rate of correction of \([Na^+]\) is critical for prevention of either prolonged brain edema or osmotic demyelination. The current standard is a controlled rate of rise in \([Na^+]\). Although there is some debate about how rapid the initial increase in \([Na^+]\) should be in severe hyponatremia, there is strong evidence that the incidence of osmotic demyelination increases sharply if the correction exceeds 20 mEq/L in the first 24 hours. Based on these observations, most experts recommend slower rates of correction. Recent guidelines from an expert panel recommend a minimum rate of correction of \([Na^+]\) by 4 to 8 mEq/L per day, and a goal of 4 to 6 mEq/L per day if the risk of osmotic demyelination syndrome is high. The expert panel set also upper limits in the rate of correction. \([Na^+]\) should not rise by more than 8 mEq/L in any 24-hour period if the risk of osmotic myelinolysis is high and by no more than 10 to 12 mEq/L in any 24-hour period or 18 mEq/L in any 48-hour period if the risk of osmotic myelinolysis syndrome is not high.

Achieving the desired rate of correction of \([Na^+]\) is a difficult task. In a recent report, the rise in \([Na^+]\) in the first 24 hours of treatment exceeded 12 mEq/L in 11% of the subjects admitted with severe hyponatremia. Saline infusion carries special risks of overcorrection of hyponatremia. The volume of infused saline is calculated by formulas that take into account the starting and target \([Na^+]\) values, the concentration of sodium in the infusion and the volume of body water before the start of saline infusion. Lack of precision, or inaccuracy, of the clinical estimates of body water entered in the formulas used to calculate the volume of infused saline required for a specific rise in \([Na^+]\), are important sources of error in the predictive formulas.

The major source of error during treatment of hyponatremia with saline infusion, however, is not accounted for in the predictive formulas. The source of this error is the volume and the concentrations of sodium and potassium of the urine during the treatment period. Two recently proposed strategies addressed specifically the effect of urine volume and composition on \([Na^+]\), during treatment of severe hyponatremia. These strategies, which include use of V2 vasopressin receptor inhibitors (vaptans) and infusion of desmopressin along with saline, have diametrically opposite effects on urinary free water excretion. Vaptans increase water loss in the urine (aquaresis) without changing urinary excretion of sodium or potassium; in contrast, desmopressin promotes water reabsorption in the collecting ducts, thereby limiting urinary water loss. It is therefore imperative to analyze the advantages, risks, indications and contraindications of these 2 treatments for the various categories of hyponatremia. The recent guidelines address some of the uses of vaptans and desmopressin in hyponatremia.

The purpose of this report was to provide a rationale, based on the pathogenetic mechanism of each episode of severe hyponatremia, for choosing vaptans or desmopressin plus saline as the method of treatment of severe hyponatremia. We do not address alternative methods (eg, restriction of fluid intake, administration of other than vaptan medications blocking the effect of vasopressin on the urinary concentrating mechanism, urea infusion), all of which may have a role in the management of severe hyponatremia in particular individuals.

RELATIONSHIP BETWEEN URINE COMPOSITION, URINE FLOW RATE AND CORRECTION OF \([Na^+]\)

As we have previously discussed, the changes in \([Na^+]\) can be predicted based on various clinical parameters, including initial body water volume, urine flow rate and electrolyte composition, infuses volume and composition as well as dietary...
ingestion and extrarenal salt and water losses. If we ignore extrarenal losses, the final serum sodium concentration after infusion of saline ([Na]_{\text{Fin}}) is predicted by the equation:

\[
[Na]_{\text{Fin}} = \frac{TBW_{\text{Ini}} \times [Na]_{\text{Ini}} + 1.11 \times V_{\text{Inf}} \times [Na]_{\text{Inf}} - V_{\text{Urine}} \times \left\{[Na]_{\text{Urine}} + [K]_{\text{Urine}}\right\}}{TBW_{\text{Ini}} + V_{\text{Inf}} - V_{\text{Urine}}},
\]

where TBW_{\text{Ini}} is total body water before the infusion, [Na]_{\text{Ini}} is the initial serum sodium concentration, 1.11 is an empiric correction term proposed by Edelman et al.11 V_{\text{Inf}} is the volume of the infusate, [Na]_{\text{Inf}} is the sodium concentration in the infusate, V_{\text{Urine}} is the volume of urine and [Na]_{\text{Urine}} and [K]_{\text{Urine}} are the concentrations of sodium and potassium in the urine, respectively.

Using this formula and assuming starting points attributable to a 70-kg man with a serum sodium of 125 mEq/L, we performed simulations shown in Figure 1. Reviewing these figures, it seems very clear that infusion of substantial amounts of hypertonic saline would be associated with very high rates of rise in [Na], unless the urine remained very concentrated. Ergo, it would be predicted that the combination of vaptan therapy, which would cause the elaboration of dilute urine, and hypertonic saline would likely result in too-rapid rates of correction. Vaptans or desmopressin are indicated in certain categories of hyponatremia and are contraindicated or ineffective in other categories.

**CATEGORIES OF HYponatREMIA**

One large group of hyponatremias is characterized by high serum vasopressin levels and urine osmolality levels that...
are higher than the levels that should normally accompany low [Na⁺] levels.⁶,⁸,¹⁰,¹² High levels of serum vasopressin are the main cause of the inability to excrete water in this group, which consists of 3 categories, hypovolemic, euvolemic and hyper-
volemic hyponatremia.⁵,¹²

Characterization of volume status in hyponatremic patients with high levels of serum vasopressin is critical but encounters serious difficulties. Historical evidence, clinical examination and certain laboratory findings have traditionally been the cornerstone of this classification.⁷,⁹,¹⁰,¹²,¹⁴ Hypovole-
mic hyponatremia is characterized by history suggesting loss of volume through the gastrointestinal tract, the kidneys or the skin, clinical findings (recent weight loss, orthostatic hypotension, orthostatic tachycardia, absence of edema) and low sodium concentration in the urine except when sodium losses occur through the urine.⁷,¹²,¹³ Euvolemic hyponatremia is char-
acterized by the absence of historical or clinical findings of volume deficit and, usually, by relatively high urine sodium concentration and low serum uric acid level.⁵,¹²,¹³ Hypervole-
mic hyponatremia is characterized by the presence of a disease causing sodium retention, absence of clinical signs of volume deficit, significant edema (≥0.5 cm of pressure-induced edema) and low urine sodium concentration.⁷,¹²,¹³

The sensitivity and specificity of clinical criteria in differentiating between hypovolemic and euvolemic hypona-
tremia are poor.¹⁴ Urine sodium concentration is low in hypov-
olemic hyponatremia except in patients with renal losses of sodium caused by disease or diuretics. Whereas, urine sodium is high in most patients with euvoletic hyponatremia except those who experience sodium losses in addition to the primary condition causing euvolemic hyponatremia.⁷,¹⁴ Serum levels of norepinephrine and renin, which are high in hypovolemic hypona-
tremia and low in euvolemic hyponatremia,¹⁴ provide bet-
ter discrimination between the 2 states. If doubts persist, careful infusion of saline in relatively small volumes and monitoring of urinary water and sodium excretion and of [Na⁺], may provide useful information about the category of hyponatremia.⁷,¹⁴ The characterization of volume status in patients with severe hypo-
natremia may benefit from application of the specialized non-
invasive and invasive techniques that are now available for assessment of intravascular volume in critically ill patients.¹⁵ However, we did not find any studies that investigated these techniques in hyponatremia.

The second group of hyponatremias is characterized by low serum vasopressin levels and typically low urine osmolari-
ity. Mechanisms other than vasopressin excess are primarily responsible for the water retention in this heterogeneous group, but vasopressin action may play a secondary role. This group includes hyponatremia in chronic renal failure,¹⁶ psychiatric disorders,¹⁷ potomania,¹⁸ low solute load excreted in the urine¹⁹ and the sick cell syndrome.²⁰ Resetting of the osmostat may present with high or low urine osmolality (see below). It will be classified in this report in the category of hyponatremia second-
ary to high vasopressin level because patients with resetting of the osmostat have high vasopressin levels and high urine osmo-
lality when they have hyponatremia.

**INDICATIONS AND CONTRAINDICATIONS OF VAPTANS AND DESMOPRESSIN WITH SALINE FOR EACH CATEGORY OF SEVERE HYPONATREMIA**

Several reports have analyzed the indications and contra-
indications of vaptan use in hyponatremia.⁷,²¹–²³ Desmopressin infusion added to the infusion of hypertonic saline, the volume of which was calculated by the Adrogue–Madina formula,⁹ achieved the desired rise in [Na⁺] in 25 of 25 patients with severe hyponatremia.²⁴ Overcorrection was not noted. The treatment with desmopressin infusion was provided to all the patients, regardless of the category of hyponatremia.²⁴ Table 1 provides synoptic answers to the question whether vaptans and desmopressin are effective and safe initial treatments in each category of severe hyponatremia. The remaining text of this section provides the rationale for the statements in Table 1.

**Hyponatremias Resulting Primarily From High Vasopressin Levels**

Inhibition of vasopressin action by vaptans will cause aquaresis and increases in [Na⁺], in every category of hypona-
tremia in this group, whereas desmopressin, which is infused to prevent aquaresis and rapid increases in [Na⁺], may be consid-
ered as ineffective given the known fact that increases in serum vasopressin levels above the level that cause maximal urine concentration physiologically (5 to 6 pg/mL) have no further effects on urine osmolality.²⁵ However, there are differences between the 3 categories of hyponatremia in the indications and risks of these treatments. Each category is analyzed below.

**Hypovolemic Hyponatremia**

In this category of hyponatremia, regardless of the mechanism of hypovolemia, vasopressin secretion is sustained by hypovolemia. Repletion of the extracellular volume by infusion of saline corrects the hypovolemia and removes the volume stimulus for vasopressin release in the circulation. Vasopressin release is then under the influence of osmolality, which is low. Thus, serum vasopressin levels become very low, resulting in profound aquaresis. Vaptans are unnecessary in this setting because production of dilute urine will inevitably follow volume repletion. In fact, vapton use to treat severe hypona-
tremia is actually dangerous. Aquaresis preceding the correction of the volume deficit will aggravate this deficit and will also result in overcorrection of hyponatremia. Reversal of hypovo-
ltemia with hypertonic or isotonic saline infusion alone carries also the risk of overcorrection of hyponatremia because it will be followed by aquaresis and a rise in [Na⁺], exceeding that calculated using the predictive formulas.² Maintenance of urine volume at the lowest rate that will allow solute excretion enhances the accuracy of the formulas that calculate the volume of infused saline and prevents overcorrection of the hyponatre-
ma.²,⁶,²⁴ Consequently, hypovolemic hyponatremia constitutes a prime indication for infusion of desmopressin along with saline.

**Euvolemic Hyponatremias**

This category consists of hyponatremias occurring in endocrine disorders, including the syndrome of inappropriate vasopressin secretion (SIADH), profound hypothyroidism and Addison’s disease. SIADH can develop in certain disease states or can complicate the use of certain drugs.³⁶ Vaptans are effec-
tive in correcting hyponatremia in this syndrome³⁷ and can be used as initial treatment. Aquaresis resulting from the use of vaptans, however, is associated with the risk of overcorrection of hyponatremia. Monitoring of [Na⁺] and urine output is imperative in this setting. Infusion of hypertonic saline is the pre-
ferrred initial step in the treatment of hyponatremia with profound neurological manifestations.³⁸ Although not danger-
ous, desmopressin infusion in the setting of persistently ele-
vated urine osmolality should be considered ineffective.

The nephrogenic syndrome of inappropriate diuresis is characterized by severe hyponatremia occurring early in life,
undetectable (very low) serum vasopressin levels and urine with high osmolality. This syndrome is caused by a missense mutation in the gene of the sex-linked V2 receptor in the basolateral membrane of the principal cells of the collecting ducts. Whether there is any place for vaptans in the treatment of hyponatremia in patients with this syndrome is not known currently. Like in SIADH, desmopressin should be ineffective in this syndrome in which the high urine osmolality will not decrease during saline infusion.

Euvolemic hyponatremia is encountered in patients with severe hypothyroidism. The proper treatment for this condition is thyroid replacement, which corrects the hyponatremia. Because a vasopressin-mediated component is part of the inability to excrete water loads in this syndrome, it is expected that vaptans will be effective in correcting hyponatremia. However, information on the effectiveness of vaptans in this syndrome is lacking. Desmopressin and saline infusion may have a place in the early treatment of severe hyponatremia if thyroid hormone replacement promptly reverses the urinary diluting defect of hypothyroidism.

Secondary adrenal insufficiency is the third hormonal deficit leading to euvolemic hyponatremia. Glucocorticoids facilitate water excretion by the kidneys. Glucocorticoid deficit is associated with a vasopressin-mediated inability to excrete water loads that responds to vaptans. However, the primary treatment for this type of hyponatremia is glucocorticoid replacement. It is possible that desmopressin added to saline infusion may be useful in the treatment of severe hyponatremia if concomitant glucocorticoid administration causes an early reversal of the diluting defect. The hyponatremia of primary adrenal insufficiency with combined glucocorticoid and mineralocorticoid deficits has an important element of volume depletion. Desmopressin infusion has a role in the simultaneous correction of hyponatremia and volume defect by infusion of saline.

The concept of resetting of the osmostat has been applied to patients presenting with hyponatremia or hypernatremia who on formal testing of urinary dilution by water loading and concentration by water deprivation behave as if they have shifted their normal Na\(_s\) downward or upward, respectively. The diagnosis of this syndrome requires exclusion of other types of hyponatremia. Resetting of the osmostat is usually seen in patients with chronic illness and can be combined with other mechanisms of water retention, such as low solute clearance. Measurement of urine osmolality and sodium concentration at presentation with hyponatremia should guide the choice of initial treatment. Hyponatremia resulting from resetting of the

---

**TABLE 1. Vaptans and desmopressin in the treatment of severe hyponatremia (effectiveness, risks, indications and contraindications).**

<table>
<thead>
<tr>
<th>Category of hyponatremia</th>
<th>Vaptans</th>
<th>Desmopressin</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. With high urine osmolality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypovolemic</td>
<td>Effective</td>
<td>Effective(^c)</td>
</tr>
<tr>
<td></td>
<td>Very high risk(^ab)</td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td>Contraindicated</td>
<td>Highly indicated</td>
</tr>
<tr>
<td>Euvolemic</td>
<td>Effective</td>
<td>Ineffective</td>
</tr>
<tr>
<td></td>
<td>High risk(^b)</td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td>Use with caution</td>
<td>Not indicated</td>
</tr>
<tr>
<td>Resetting of the osmostat</td>
<td>Effective in some cases</td>
<td>Effective in some cases</td>
</tr>
<tr>
<td></td>
<td>High risk(^b)</td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td>Unknown usefulness</td>
<td>Indicated if hypovolemia is also present</td>
</tr>
<tr>
<td>Hypervolemic</td>
<td>Effective</td>
<td>Ineffective</td>
</tr>
<tr>
<td></td>
<td>High risk(^b)</td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td>Use with caution</td>
<td>Not indicated</td>
</tr>
<tr>
<td>A. With typically low urine osmolality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>Limited effectiveness</td>
<td>Limited effectiveness</td>
</tr>
<tr>
<td></td>
<td>Low risk</td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td>Questionable usefulness</td>
<td>Questionable usefulness</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Limited effectiveness</td>
<td>Effective</td>
</tr>
<tr>
<td></td>
<td>High risk(^b)</td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td>Not indicated</td>
<td>Indicated</td>
</tr>
<tr>
<td>Beer potomania</td>
<td>Limited effectiveness</td>
<td>Effective</td>
</tr>
<tr>
<td></td>
<td>High risk(^b)</td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td>Not indicated</td>
<td>Indicated</td>
</tr>
<tr>
<td>Low urinary solute load</td>
<td>Ineffective</td>
<td>Effective</td>
</tr>
<tr>
<td></td>
<td>High risk(^b)</td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td>Not indicated</td>
<td>Indicated</td>
</tr>
<tr>
<td>Sick cell syndrome</td>
<td>Unknown effectiveness</td>
<td>Unknown effectiveness</td>
</tr>
<tr>
<td></td>
<td>Unknown risks</td>
<td>Unknown risks</td>
</tr>
<tr>
<td></td>
<td>Unknown usefulness</td>
<td>Unknown usefulness</td>
</tr>
</tbody>
</table>

\(^a\) Risk of worsening hypovolemia.

\(^b\) Risk of overcorrection of hyponatremia.

\(^c\) Effective after correction of hypovolemia and removal of the volume stimulus for vasopressin release.
osmostat should respond to vaptans. However, early use of vaptans should be avoided. Desmopressin infusion is indicated if a component of hypovolemia or of low solute availability is suspected. In euvolemic hyponatremia treated with hypertonic saline, infusion of large loop diuretics promotes urinary water losses and can be used instead of vaptans. Frequent monitoring of the serum sodium concentration is imperative in this setting.

**Hyponatremias Resulting Primarily From Mechanisms Other Than Vasopressin Release**

### Hyponatremia of Chronic Renal Failure

Hyponatremia in chronic renal failure is typically associated with hypertovolemia and is often classified as hypervolemic hyponatremia. However, the mechanism of hyponatremia differs between chronic renal failure and the conditions listed in this report under hypervolemic hyponatremia. These conditions have high serum vasopressin levels and high osmolality values in the urine. The ability of the kidneys to produce urine with very low osmolality is preserved in chronic renal failure. In this syndrome, water loading leads to formation of dilute urine. Hyponatremia develops in this setting because the volume of water that the kidneys are capable to excrete is too low and can be less than even usual volumes of ingested water. Loop diuretics may increase water diuresis in hyponatremic patients with substantial residual renal function.

In contrast to urinary dilution, urine concentration is impaired in chronic renal failure. The concentrating defect is resistant to vasopressin infusion. Low levels of both the V2 receptor and aquaporin-2 have been found in renal failure. However, experimental animals with renal failure responded to water restriction with a weak increase in aquaporin-2, a decrease in urine volume and an increase in urine osmolality. Vaptan administration to patients with severe chronic renal failure and congestive heart failure increased urine volume and modestly decreased urine osmolality. Thus, vaptans may have a role in the management of hyponatremia of chronic renal failure. Desmopressin infusion will not be needed because of the limited ability of the kidneys to excreted free water.

### Hyponatremia of Psychiatric Disorders

Several categories of drugs used to treat psychiatric disorders can cause SIADH. In addition, primary polydipsia with hyponatremia is encountered in large numbers of patients with various psychiatric diagnoses. Most patients with primary polydipsia have a dilute urine. In a number of patients, however, serum vasopressin was not suppressed adequately. Because the urine is not maximally diluted, hyponatremia in these patients may respond to vaptans. However, the main issue with the treatment of hyponatremia in the setting of excessive fluid intake is that cessation of water intake, which is the primary treatment, may lead to an inappropriately rapid rise in [Na⁺], because of a large volume of dilute urine. Desmopressin infusion is indicated, but with a note of caution. Impaired abundance of aquaporin-2 protein in this syndrome may limit the effectiveness of desmopressin.

### Hyponatremia in Beer Potomania

Excessive fluid intake without any other abnormalities leads to a characteristic picture of very low to undetectable serum vasopressin concentration and a dilute urine, with an osmolality less than 100 mOsm/kg. However, beer drinkers developing hyponatremia exhibit a variety of biochemical profiles. Specifically, urine osmolality is >100 mOsm/kg in several subjects, whereas urine sodium concentration may be <20 mmol/L suggesting hypovolemia, >40 mmol/L suggesting SIADH, reset osmostat or salt wasting and between 20 and 40 mmol/L. In this last category, a large rise in [Na⁺] after infusion of a test volume of isotonic saline suggests the presence of hyponatremia. Low solute intake may contribute to the inability to excrete the ingested loads of fluid. The use of vaptans may assist in the elucidation of the mechanism of hyponatremia in patients with beer potomania but is associated with a risk of overcorrection of hyponatremia similar to the risk in hypovolemic hyponatremia. Saline infusion also carries a risk of overcorrection of hyponatremia, particularly in patients with hypovolemia. The indication for desmopressin infusion in this setting is strong.

### Hyponatremia in Patients With Low Urinary Solute Load

These patients present with dilute urine. However, their ability to excrete water loads is severely limited even when their urine osmolality is at the lowest attainable level. Vaptans should have no effect on water excretion when urine dilution is maximal. Solute administration, in the form of saline infusion, rapidly increases free water excretion. Desmopressin infusion, along with saline, hypertonic or isotonic, is indicated in the initial phase of treatment of severe hyponatremia in this syndrome.

### Hyponatremia in Patients With Sick Cells

The concept of sick cells refers to abnormalities in the function of transport processes of the cell membranes in patients with severe illnesses, with exit of low-molecular-weight organic solutes and water into the extracellular...
compartment. The characteristic biochemical picture is one of hyponatremia, normal serum osmolality and a large osmol gap, which is the difference between measured serum osmolality and osmolality calculated as the sum of the osmotic equivalents of serum sodium, glucose and urea. The concept of sick cell as a cause of hyponatremia has been disputed. Even if this syndrome causes hyponatremia, the changes in cell volume should be opposite in the sick cell syndrome, in which cells lose water, and other hyponatremias in which cells are swollen. The role of vaptans or desmopressin in the management of this syndrome is unclear.

Figure 2 shows a flow chart of treatment of hyponatremias with a focus on the use of vaptans or desmopressin.

CONCLUSIONS

The use of vaptans for initial treatment of severe hyponatremia is associated with serious risks and is ineffective in certain categories of hyponatremia. The risks of desmopressin infusion are not significant. However, this compound will be ineffective in hyponatremia with persistently elevated urine osmolality. Cost and side effects of each treatment should also be taken into account if alternative treatments are available. Vaptans are effective in correcting hyponatremia with high levels of serum vasopressin and high urine osmolality values. They can be used as initial treatment of hyponatremias with urine osmolality that is persistently elevated but should never be used simultaneously with hypertonic saline. The risk of overcorrection of \( [Na] \) is very high in this case. Vaptans are contraindicated in hyponatremias with urine osmolality that is high initially but is lowered after saline infusion and they are ineffective in hyponatremia with dilute urine. Desmopressin infusion is ineffective for hyponatremias with persistently high urine osmolality but offers the best option for preventing overcorrection of severe hyponatremia with urine that is initially dilute.

FIGURE 2. Initial management of severe hyponatremia.
concentrated but responds to saline infusion with dilution. Desmopressin infusion is also indicated for most categories of severe hyponatremia with dilute urine. Characterization of the volume status is critical for the choice of treatment. Hyponatremia in hyponatremic patients may not be detectable by clinical means. Use of desmopressin as initial treatment of hyponatremia if there are doubts about the presence of hyponatremia is prudent. Monitoring of [Na⁺], urine flow rate and, in selected cases, urine sodium and potassium concentration is critical during treatment of severe hyponatremia regardless of the method of treatment. Monitoring should be intensified if vaptans are used. The use of vaptans or desmopressin in certain types of hyponatremia will require further studies.

REFERENCES


16. Gross P, Rascher W. Vasopressin and hyponatremia in renal insuffi-

17. de Leon J, Verghese C, Tracy JI, et al. Polydipsia and water intox-

20. Gill GV, Ospiv JC, Shearer E, et al. Critical illness with hypona-

tramia and impaired cell membrane integrity—the “sick cell syn-

21. Jovanovich AJ, Berl T. Where vaptans do and do not fit in the treat-


25. Robertson GL. Thirst and vasopressin function in normal and disor-


33. Leehey DJ, Picache AA, Robertson GL. Hyponatremia in quadriple-

34. Schrier RW. Pathogenesis of sodium and water retention in high-

35. Schrier RW. Pathogenesis of sodium and water retention in high-

36. Schrier RW. Body fluid volume regulation in health and disease: a uni-

37. Schrier RW, Gross P, Georgiade M, et al, SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hy-

38. Torres VE, Chapman AB, Devuyst O, et al. TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycys-


40. Tannen RL, Regal EM, Dunn MJ, et al. Vasopressin-resistant hypo-


